Enfortumab vedotin plus pembrolizumab in cisplatin‐eligible muscle‐invasive bladder cancer: efficacy proven, duration unclear

Massimiliano Depalma, Francesco Rossi, Matteo Ferro, Laura Bukavina, Giuseppe Di Lorenzo, Riccardo Autorino
BJU International · Wiley · 2026-10-21 · DOI: 10.1111/bju.70507

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles